GLP-1 oral research
99%+ · 0.5mg · Tablets · MW: 4113.58
Bulk discount
3+ pcs
€90.25
−5%
5+ pcs
€85.50
−10%
10+ pcs
€80.75
−15%
Discount is applied automatically at checkout.
Enter your email and we'll notify you when it's back:
Free shipping over €49
This product is sold strictly for in lab conditions (in vitro) research purposes. Not approved for human consumption.
Verified above 98%
98%+ guaranteed — most batches reach 99%+
Included
Independent analysis from accredited laboratories
EU Shipping
1-3 days across the EU (Bulgaria — 1-2 days)
Secure Payment
Card via Stripe or Cash on Delivery
Semaglutide Tablets 500 mcg × 25
GLP-1 Receptor Agonist | Oral Tablet Format | Weight Management Research
In short
Reduces appetite and helps with effective weight loss without the constant feeling of hunger.
Best sellers
Related resources
Scientific review
Калина Тодорова
Magister Pharmaciae, MSc Pharmacy
Reviewed on
Semaglutide is a long-acting GLP-1 receptor agonist that shares 94% sequence homology with native human GLP-1. The C18 fatty-acid side chain and three amino-acid substitutions yield a ~165-hour plasma half-life, an order of magnitude longer than first-generation GLP-1 analogs like Liraglutide. The compound is marketed as Ozempic (T2D) and Wegovy (obesity) in injectable form by Novo Nordisk; an oral version (Rybelsus) is also approved at 3, 7, and 14 mg doses. This oral tablet research format supports investigation of absorption variability, dose-response curves outside the approved indications, and head-to-head comparisons with newer dual and triple agonists.
~165h plasma half-life — weekly-equivalent injectable dosing STEP-1 trial: 14.9% body-weight reduction at 2.4 mg/week (NEJM 2021) SUSTAIN-7 head-to-head: superior to Dulaglutide for HbA1c Oral research format for absorption studies
Semaglutide binds to and activates the GLP-1 receptor (GLP-1R) on pancreatic β-cells, hypothalamic neurons, and gastrointestinal smooth muscle. Receptor activation potentiates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and produces central appetite suppression via hypothalamic signaling. Unlike sulfonylureas, the insulinotropic effect is strictly glucose-dependent — minimizing hypoglycemia risk in research models with intact pancreatic function.
STEP-1 (NEJM 2021, n=1961) demonstrated 14.9% body-weight reduction at 2.4 mg weekly s.c. over 68 weeks. Oral tablet research investigates whether comparable effects can be achieved via gastric absorption.
Gastrointestinal events — nausea, vomiting, diarrhea, constipation — are the most frequently reported adverse effects in clinical research. Acute pancreatitis is a recognized signal in long-term trials and warrants discontinuation if suspected. Thyroid C-cell tumors have been observed in rodent models; the human relevance remains under investigation. Use is contraindicated in models with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Compatibility
The pairings below come from research literature and established biohacker stacking patterns. Click a card for the full reasoning - when the partner is in our catalog you'll see a direct order link too.
This is a literature overview, not medical advice. Pairs not listed are not proven safe - they simply lack enough published data.
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Human | 1961 participants | 68 weeks | NEJM 2021
Wilding et al. demonstrated 14.9% mean body-weight reduction with 2.4 mg weekly subcutaneous semaglutide over 68 weeks in non-diabetic adults with overweight/obesity.
View the studySemaglutide vs Dulaglutide in T2D (SUSTAIN-7)
Human | 1201 participants | 40 weeks | Lancet Diabetes Endocrinol 2018
Pratley et al. found semaglutide superior to dulaglutide for HbA1c reduction (-1.5% vs -1.1%) and body weight (-6.5kg vs -3.0kg) at 40 weeks.
View the study
Out of stockfor visceral fat
for weight loss
No reviews yet. Be the first.
Share your experience with this peptide. We publish after a short moderation.
